MétaCan
Menu
← Back to cohort
Record W7106811895 · doi:10.5281/zenodo.17707543

NEURO-Restore: Convergent Computational and Mathematical Validation of Multi-Target Neuroinflammatory Modulation in Alzheimer's Disease—Independent Pathways to 31-40× Therapeutic Superiority

2025· article· W7106811895 on OpenAlexaboutno aff

Bibliographic record

VenueZenodo (CERN European Organization for Nuclear Research) · 2025
Typearticle
Language
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsnot available
Fundersnot available
KeywordsBiomarkerMathematical proofKey (lock)Computational modelReduction (mathematics)Modelling biological systemsDrug target

Abstract

fetched live from OpenAlex

This submission presents NEURO-Restore v3.0, a novel multi-target therapeutic formulation for Alzheimer's disease (AD) with projected 31-40× superiority over current FDA-approved treatments. The work establishes convergent validation through two independent computational systems developed on separate continents: Framework 50 (AI-guided multi-target optimization) and IMMUNO-SERENE v3.0 (mathematical neuroimmune dynamics modeling). Key Findings:• Both independent systems converged on identical therapeutic targets and predicted 31-40× superiority over lecanemab (current standard-of-care)• Projected 12-week MMSE improvement: 14.1±2.8 points vs. lecanemab's 0.45 points over 18 months• Addresses all six core AD pathologies simultaneously: amyloid burden, tau aggregation, neuroinflammation, cholinergic deficit, mitochondrial dysfunction, and vascular compromise• Based on Nigella sativa platform with 80-100 molecular targets and 1,400 years of human safety data Projected Biomarker Improvements (12 weeks):• Plasma p-Tau: 80% reduction (vs. lecanemab 12%)• CSF Aβ42/Aβ40 ratio: 115% improvement (vs. lecanemab 22%)• Serum BDNF: 350% increase (vs. lecanemab 8%)• Plasma TNF-α: 85% reduction (vs. lecanemab 18%)• Erythrocyte ATP/ADP: 110% improvement (vs. lecanemab 5%) Methodological Innovation:The convergent validation approach eliminates single-pathway bottlenecks in complex disease drug development. When independent computational and mathematical methodologies reach identical conclusions, the probability of mechanistic error approaches zero. Regulatory Significance:This work meets FDA Breakthrough Therapy Designation criteria and establishes a novel regulatory framework for multi-target therapeutics in complex diseases. The approach applies proven multi-target principles from HIV (HAART) and cancer therapeutics to neurodegeneration. Contents:• Complete manuscript submitted to Nature Medicine• Supplementary Information with mathematical proofs and validation datasets• Framework 50 validation results• Biomarker datasets and protocols• Response to reviewers• Target engagement profiles Authors: Mohamad Al-Zawahreh (Framework 50 Developer, Ottawa) and Michał Wójtków (IMMUNO-SERENE Developer, Poland) Submission Date: November 24, 2025

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: Simulation or modeling
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.050
GPT teacher head0.291
Teacher spread0.241 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSimulation or modeling
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueZenodo (CERN European Organization for Nuclear Research)→Same topicAlzheimer's disease research and treatments→French-language works237,207→